VIDEO: Pipeline 'super robust' for multiple myeloma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The good news in myeloma is that the pipeline is super robust, and this has been happening because of tremendous access to a large amount of genomics data. We have transcriptomic data, we have whole genome and other sequencing data. So, there are two to three areas of great significance. One is further developing the immunotherapeutic approaches, various versions of CAR T cells, finding bispecifics, trispecifics, etc. So, developing further new targets and new treatments focused on immunotherapeutic approaches. The second component ends up being still further developing the currently available therapies, which includes, for example, newer generation of immunomodulatory reagent — for example two in pipeline are iberdomide and mezigdomide. They are new generation of Revlimid [Bristol Myers Squibb] and pomalidomide. And then there are other newer compounds by other entities also targeting similarly IKZF and other molecules. Then there are developments that target protein catabolism — bortezomib, or Velcade [Takeda Oncology]. These are very well-known examples to start with for proteasome inhibitor, but there are newer agents which go in that line. And then, finally, one of the new areas that I think has no yet approved drug, and just beginning to have talks about translating some of that data into clinic, but there’s a whole new area of long non-coding RNA or non-coding RNA in general, that are supposed to play a significant role in cellular biology, even more so in tumor biology, and very specifically we have described its role in myeloma biology. And having drugs targeting those non-coding RNA or long non-coding RNA is going to be another important future area of research, which may impact significantly how we treat multiple myeloma in the near future.